The discovery that GLP-1 receptor agonists (GLP-1RAs), previously approved for the treatment of type 2 diabetes [14,15], reduce energy intake alongside increasing insulin secretion and inhibiting gastric emptying [13], reinvigorated the field of obesity pharmacotherapy, with the development and approval of the long-acting GLP-1RAs liraglutide and semaglutide [16,17]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.